DI MARTINO, MARIA TERESA
 Distribuzione geografica
Continente #
NA - Nord America 870
AS - Asia 785
EU - Europa 718
SA - Sud America 127
AF - Africa 38
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.547
Nazione #
US - Stati Uniti d'America 827
IT - Italia 383
SG - Singapore 332
CN - Cina 123
IN - India 108
BR - Brasile 99
DE - Germania 89
GB - Regno Unito 73
VN - Vietnam 47
FI - Finlandia 40
HK - Hong Kong 30
CA - Canada 26
NL - Olanda 26
PK - Pakistan 22
SE - Svezia 22
ID - Indonesia 21
JO - Giordania 21
ZA - Sudafrica 14
BD - Bangladesh 12
ES - Italia 12
FR - Francia 11
MX - Messico 11
SA - Arabia Saudita 11
EG - Egitto 10
CO - Colombia 9
RU - Federazione Russa 9
AE - Emirati Arabi Uniti 7
AR - Argentina 7
CZ - Repubblica Ceca 7
IQ - Iraq 7
JP - Giappone 7
LT - Lituania 7
PE - Perù 7
PT - Portogallo 7
AU - Australia 6
NG - Nigeria 6
TR - Turchia 6
AT - Austria 5
ET - Etiopia 5
IE - Irlanda 5
IR - Iran 5
LB - Libano 5
CY - Cipro 4
EC - Ecuador 4
MY - Malesia 4
PL - Polonia 4
UA - Ucraina 4
BG - Bulgaria 3
CH - Svizzera 3
GT - Guatemala 3
KR - Corea 3
PH - Filippine 3
RO - Romania 3
AL - Albania 2
HN - Honduras 2
HR - Croazia 2
LK - Sri Lanka 2
MA - Marocco 2
PS - Palestinian Territory 2
A2 - ???statistics.table.value.countryCode.A2??? 1
EE - Estonia 1
EU - Europa 1
KE - Kenya 1
NZ - Nuova Zelanda 1
OM - Oman 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 2.547
Città #
Singapore 178
Chandler 110
Ashburn 75
Dallas 72
Munich 63
Santa Clara 53
Bengaluru 47
Hefei 46
Chicago 43
London 40
Turku 29
Milan 27
Beijing 24
Lawrence 24
Princeton 24
Ho Chi Minh City 20
Hong Kong 20
Rome 20
Los Angeles 18
Catanzaro 17
Amman 13
Naples 13
New York 13
Boardman 12
Carbonia 12
Parma 12
San Nicola Manfredi 12
Helsinki 11
San Francisco 10
Spezzano della Sila 10
São Paulo 10
Palermo 9
Wilmington 9
Council Bluffs 8
Delhi 8
Frankfurt am Main 8
Hanoi 8
Irbid 8
Cosenza 7
Des Moines 7
Kaunas 7
Madrid 7
Montreal 7
Ottawa 7
Afragola 6
Catania 6
Ercolano 6
Hyderabad 6
Riyadh 6
Santo Stefano di Rogliano 6
Sezze 6
Atlanta 5
Brooklyn 5
Cape Town 5
Cardiff 5
Chennai 5
Jeddah 5
Lucknow 5
Melito di Porto Salvo 5
Meppel 5
Olomouc 5
Pune 5
Sacramento 5
Seattle 5
Tokyo 5
Addis Ababa 4
Ahmedabad 4
Da Nang 4
Hanover 4
Islamabad 4
Johannesburg 4
Kuala Lumpur 4
Lima 4
Nicosia 4
Oristano 4
Perugia 4
Redmond 4
Stockholm 4
The Dalles 4
Tubarão 4
Warsaw 4
West Jordan 4
Acquaviva delle Fonti 3
Ajman 3
Amsterdam 3
Banyumas 3
Berlin 3
Bristol 3
Buffalo 3
Campina Grande 3
Can Tho 3
Castrovillari 3
Charlotte 3
Chía 3
Decollatura 3
Dhaka 3
Dubai 3
Faisalabad 3
Istanbul 3
Melbourne 3
Totale 1.412
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 405
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 116
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 95
miR-22 suppresses DNA ligase III addiction in multiple myeloma 95
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 78
Augmented reality (AR) in minimally invasive surgery (MIS) training: where are we now in Italy? The Italian Society of Endoscopic Surgery (SICE) ARMIS survey 73
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 69
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 67
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 67
A 46,XY Female with a 9p24.3p24.1 Deletion and a 8q24.11q24.3 Duplication: A Case Report and Review of the Literature. 66
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 65
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 63
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 61
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 57
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 55
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 55
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 52
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 52
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 51
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 51
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 49
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 48
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 48
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 47
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 46
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 46
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 43
Mmrf-commpass data integration and analysis for identifying prognostic markers 43
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 43
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 42
An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery 39
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 38
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 37
Ethical Perspectives on Pharmacogenomic Profiling 35
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 34
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 33
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 31
null 31
Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience 30
LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation 30
A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer 29
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 27
Hit identification of novel small molecules interfering with MALAT1 triplex by a structure-based virtual screening 26
Current status of liver surgery for non-colorectal non-neuroendocrine liver metastases: the NON.LI.MET. Italian Society for Endoscopic Surgery and New Technologies (SICE) and Association of Italian Surgeons in Europe (ACIE) collaborative international survey 23
The potential role of miRNAs in multiple myeloma therapy 23
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 20
The EASY-NET research programme: background, structure, and methodology 19
null 4
Totale 2.657
Categoria #
all - tutte 19.940
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.940


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202144 0 0 0 0 10 5 6 7 6 9 1 0
2021/2022126 3 0 0 22 5 0 4 21 34 15 17 5
2022/2023394 55 25 28 13 45 26 6 25 49 40 55 27
2023/2024476 90 33 42 39 45 71 25 41 10 18 27 35
2024/2025876 75 20 27 37 64 119 64 55 55 21 142 197
2025/2026689 108 154 126 149 152 0 0 0 0 0 0 0
Totale 2.657